Healthcare
CSL’s sweeping restructure has hammered its share price, but the Allan Gray chief investment officer says the shift may finally make the biotech a buy.
AI is expected to radically speed up drug discovery. But Australia risks falling behind.
The market darling's results will take centre stage, but a bet on an ASX minnow has set tongues wagging at the smaller end of the market.
